The Prognostic Significance of Complete Response Rates in Patients with Extensive Stage Small Cell Lung Cancer

Abstract

OBJECTIVESmall cell lung cancer (SCLC) is the most aggressive type of lung cancer. Platinum-etoposide chemotherapy combination is used as first line treatment. The aim of this trial is evaluate the effect of completeresponse rates and clinical features in patients with extensive stage (ES) SCLC.METHODSIn this retrospective study, a total of 117 patients from four different oncology centers in Turkey between2011 and 2017 were divided into 2 groups, namely, patients with complete response (group 1) and thosewith no complete response (group 2) after platin-etoposide combination therapy.RESULTSThe median age of the patients was 61 (range 38-81) years.The median follow-up time was 12 monthsand 95 (81%) patients died. Progression-free survival (PFS) and overall survival (OS) were estimated,respectively, as 8 and 13 months. Overall survival of group 1 patients was statistically significantly betterthan the group 2 (16 versus 10 months respectively and p=0.00). The overall survival of patients whohad late recurrent disease (>6 mo.) was statistically significantly better than the early ones (